Novel ECG Technology Utilizes AI for Early Detection of Heart Disease
By HospiMedica International staff writers Posted on 07 Feb 2023 |
Cardiovascular disease is responsible for 17.9 million deaths every year, or about 32% of all deaths worldwide. Every week, millions of electrocardiographs (ECGs) are performed across the world, making the ECG the most ubiquitous cardiac test. However, conventional ECGs have always played a limited role in evaluating cardiac dysfunction due to their limited sensitivity in identifying structural and ischemic heart disease, thereby significantly reducing their utility in heart disease screening. Now, the ECG could become a far more valuable screening tool for the early detection of heart disease through the use of artificial intelligence (AI).
Heart Test Laboratories, Inc. (Southlake, TX, USA) has developed MyoVista Wavelet ECG (wavECG) cardiac testing device based on the recent understanding that most forms of heart disease are associated with left ventricular (LV) relaxation abnormalities and left ventricular diastolic dysfunction (LVDD). The MyoVista wavECG Device assists physicians in the detection of abnormal LV relaxation that could have been caused by heart disease. The 12-lead resting ECG device not only provides all conventional ECG information but also incorporates an AI algorithm for the detection of cardiac dysfunction.
The MyoVista wavECG Device features wavECG technology along with the capabilities of a full featured conventional 12-lead resting ECG, including analysis using the University of Glasgow Algorithm, which is among the most respected interpretive algorithms in the world. The MyoVista wavECG Device uses wavelet signal processing to extract frequency information from the acquired ECG signal which is then analyzed using AI. The additional wavECG Information provided by the MyoVista Device can assist physicians in determining if a patient should receive further testing, evaluation and/or treatment. The conventional ECG and MyoVista wavECG test results are displayed independently.
“Artificial intelligence is transforming what’s possible, and at HeartSciences we are at the leading edge of changing what’s possible with an ECG by applying AI to make it a far more valuable screening tool for heart disease detection to save lives,” said Andrew Simpson, Chief Executive Officer of HeartSciences.
Related Links:
Heart Test Laboratories, Inc.
Latest Critical Care News
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events